Sbir phase I: sprayable hydrogel sealant for gastrointestinal wound protection

Ended Project Grant Awarded Last action

Award ID
2335845
Recipient
Awarding agency
Obligated
$275,000

Award facts

Completion date
Originally
Place of performance
Boston, MA 02134, USA

Award details come from USAspending.gov.

Description

As the agency reported it.

Abstract
The broader impact/commercial potential of this small business innovation research (SBIR) phase I project centers on improving wound closure methods in minimally invasive procedures, such as endoscopy and robotic surgery. By harnessing innovative hydrogel technology based on biocompatible, biodegradable polymers, this project aims to establish a resilient barrier over surgical wounds and perforations. This transformative approach, devoid of cumbersome metal clips, promises to avert delayed bleeding, perforations, infections, and post-procedural complications. Initially designed for the gastrointestinal tract, the technology caters to unmet clinical needs, extending to applications in cardiovascular and lung sealing. The societal impact is evident in improved patient outcomes and reduced healthcare costs, while the commercial potential includes widespread adoption of a superior wound closure solution. This small business innovation research (SBIR) phase I project focuses on the development of a versatile, sprayable sealant kit that delivers prolonged protection for gastrointestinal wounds. Employing multiple adhesion mechanisms, the technology ensures sustained adhesion across biological surfaces. Delivered via a catheter, IT seamlessly integrates with commercial endoscopes and minimally invasive devices, optimizing surgical workflow. The project objectives involve the refinement of the adhesive formulation to meet gastrointestinal requirements and rigorous comparative testing. Anticipated technical outcomes encompass enhanced procedure efficiency, reduced complication rates, and improved wound healing, positioning this innovation as a transformative force in minimally invasive surgery. This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the foundation's intellectual merit and broader impacts review criteria.- subawards are not planned for this award.

Transactions

Action Obligated Date
Amendment $0
Original award $275,000

Quick answers

Who received award 2335845?

2335845 was awarded to Biodevek Inc. by National Science Foundation on December 1, 2023.

How much is award 2335845 worth?

$275,000 has been obligated on 2335845.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award
Try for free Login